2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1886

Evaluation of a New Educational Tool: A Resident’s Guide to Pediatric Rheumatology
Abstract Number: 179

Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome
Abstract Number: 1047

Evaluation of Ankle Swelling Due to Löfgren´s Syndrome: A Pilot Study Using B –mode and Power Doppler Ultrasonography
Abstract Number: 320

Evaluation of Anti-Citrullinated Type II Collagen and Anti-Citrullinated Vimentin Antibodies in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 2362

Evaluation of Disease Activity Using FDG PET-CT in Patients with Large Vessel Vasculitis
Abstract Number: 1106

Evaluation of Foot Posture and Plantar Pressure Changes in Knee Osteoarthritis: Preliminary Report
Abstract Number: 1284

Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Abstract Number: 120

Evaluation of Joint Involvement in Patients Suffering From Early Polymyalgia Rheumatica Using High Resolution Ultrasound
Abstract Number: 1266

Evaluation of Metabolic Syndrome in 97 Patients with Rheumatoid Arthritis
Abstract Number: 1362

Evaluation of Spondyloarthritis activity by the Patients and the Physicians: ASDAS, Basdai, PASS and Flare
Abstract Number: 1926

Evaluation of Strategies to Taper Anti-TNF Drugs in Patients with Inflammatory Rheumatic Disease (Rheumatoid Arthritis, Ankyloing Spondylitis, Psoriatic Arthritis, Adult-age Juvenile Idiopatic Arthritis) in Long-Term Remission
Abstract Number: 1

Evaluation of Synovial Inflammation Assessed by Macroscopic and Histological Criteria in Patients with Knee Osteoarthritis
Abstract Number: 1831

Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Abstract Number: 2378

Evaluation of the EULAR/ACR 2012 Classification Criteria for Polymyalgia Rheumatica: Comparison of the New Algorithms with and without Ultrasound to the Formerly Used Criteria
Abstract Number: 2217

Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].